# A Phase 1b Study of STMC-103H in Multi-Sensitized Allergic Subjects Who Are Otherwise Healthy

> **NCT03819881** · PHASE1 · UNKNOWN · sponsor: **Siolta Therapeutics, Inc.** · enrollment: 60 (estimated)

## Conditions studied

- Atopic Immunoglobulin E-Mediated Allergic Disorder

## Interventions

- **BIOLOGICAL:** STMC-103H
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT03819881
- **Lead sponsor:** Siolta Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10-10
- **Primary completion:** 2019-11
- **Final completion:** 2019-11
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2019-01-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03819881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03819881, "A Phase 1b Study of STMC-103H in Multi-Sensitized Allergic Subjects Who Are Otherwise Healthy". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03819881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*